These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genomics of postvaccination SARS-CoV-2 infections during the Delta dominated second wave of COVID-19 pandemic, from Mumbai Metropolitan Region (MMR), India. Nilgiriwala K; Kadam P; Patel G; Shaikh A; Mestry T; Vaswani S; Sakthivel S; Poojary A; Gandhi B; Rohra S; Udwadia Z; Oswal V; Shah D; Gomare M; Sriraman K; Mistry N J Med Virol; 2022 Sep; 94(9):4206-4215. PubMed ID: 35578378 [TBL] [Abstract][Full Text] [Related]
3. Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: A retrospective observational study from a cancer hospital in eastern India. Bhattacharya S; Chatterji S; Chandy M; Mahajan AY; Goel G; Mishra D; Vivek P; Das P; Mandal S; Chugani A; Mittal A; Perumal RC; Ramprasad VL; Gupta R Indian J Med Microbiol; 2023; 41():104-110. PubMed ID: 36244851 [TBL] [Abstract][Full Text] [Related]
4. Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford-AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach. Rahaman MM; Sarkar MMH; Rahman MS; Islam MR; Islam I; Saha O; Akter S; Banu TA; Jahan I; Habib MA; Goswami B; Bari L; Malek MA; Khan MS J Med Virol; 2022 Apr; 94(4):1670-1688. PubMed ID: 34939673 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Doke PP; Mhaske ST; Oka G; Kulkarni R; Muley V; Mishra AC; Arankalle VA Front Public Health; 2022; 10():1040012. PubMed ID: 36711329 [TBL] [Abstract][Full Text] [Related]
6. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India. Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977 [TBL] [Abstract][Full Text] [Related]
8. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. Yang W; Shaman J medRxiv; 2021 Nov; ():. PubMed ID: 34845460 [TBL] [Abstract][Full Text] [Related]
9. Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City. Robilotti EV; Whiting K; Lucca A; Poon C; Guest R; McMillen T; Jani K; Solovyov A; Kelson S; Browne K; Freeswick S; Hohl TM; Korenstein D; Ruchnewitz D; Lässig M; Łuksza M; Greenbaum B; Seshan VE; Esther Babady N; Kamboj M Clin Infect Dis; 2022 Aug; 75(1):e774-e782. PubMed ID: 34644393 [TBL] [Abstract][Full Text] [Related]
10. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. Al-Emran HM; Hasan MS; Ahasan Setu MA; Rahman MS; Alam ARU; Sarkar SL; Islam MT; Islam MR; Rahman MM; Islam OK; Jahid IK; Hossain MA J Infect Public Health; 2022 Feb; 15(2):156-163. PubMed ID: 34952247 [TBL] [Abstract][Full Text] [Related]
11. Analysis of SARS-CoV-2 genomic surveillance data during the Delta and Omicron waves at a Saudi tertiary referral hospital. Obeid D; Al-Qahtani A; Almaghrabi R; Alghamdi S; Alsanea M; Alahideb B; Almutairi S; Alsuwairi F; Al-Abdulkareem M; Asiri M; Alshukairi A; Alkahtany J; Altamimi S; Mutabagani M; Althawadi S; Alanzi F; Alhamlan F J Infect Public Health; 2023 Feb; 16(2):171-181. PubMed ID: 36543031 [TBL] [Abstract][Full Text] [Related]
12. Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India. Singh P; Sharma K; Singh P; Bhargava A; Negi SS; Sharma P; Bhise M; Tripathi MK; Jindal A; Nagarkar NM Microb Pathog; 2022 Mar; 164():105404. PubMed ID: 35065253 [TBL] [Abstract][Full Text] [Related]
13. Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. Gupta N; Kaur H; Yadav PD; Mukhopadhyay L; Sahay RR; Kumar A; Nyayanit DA; Shete AM; Patil S; Majumdar T; Rana S; Gupta S; Narayan J; Vijay N; Barde P; Nataraj G; B AK; Kumari MP; Biswas D; Iravane J; Raut S; Dutta S; Devi S; Barua P; Gupta P; Borkakoty B; Kalita D; Dhingra K; Fomda B; Joshi Y; Goyal K; John R; Munivenkatappa A; Dhodapkar R; Pandit P; Devi S; Dudhmal M; Kinariwala D; Khandelwal N; Tiwari YK; Khatri PK; Gupta A; Khatri H; Malhotra B; Nagasundaram M; Dar L; Sheikh N; Shastri J; Aggarwal N; Abraham P Viruses; 2021 Sep; 13(9):. PubMed ID: 34578363 [TBL] [Abstract][Full Text] [Related]
14. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073 [TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548 [TBL] [Abstract][Full Text] [Related]
16. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493 [TBL] [Abstract][Full Text] [Related]
17. Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. Duerr R; Dimartino D; Marier C; Zappile P; Levine S; Francois F; Iturrate E; Wang G; Dittmann M; Lighter J; Elbel B; Troxel AB; Goldfeld KS; Heguy A EBioMedicine; 2022 Aug; 82():104141. PubMed ID: 35906172 [TBL] [Abstract][Full Text] [Related]
18. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. Jung J; Kim JY; Park H; Park S; Lim JS; Lim SY; Bae S; Lim YJ; Kim EO; Kim J; Park MS; Kim SH JAMA Netw Open; 2022 May; 5(5):e2213606. PubMed ID: 35608859 [TBL] [Abstract][Full Text] [Related]
19. The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021. Bhanothu V; Munne K; Pande S; Singh P; Jagtap D; Aranha C; Gogoi D; Bhagat S; Gaonkar R; Kerkar S; Shah K; Mukherjee N; Bhor V; Patel V; Mahale SD; Sachdeva G; Begum S Arch Virol; 2023 Jun; 168(7):188. PubMed ID: 37351663 [TBL] [Abstract][Full Text] [Related]
20. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]